📰 History Study News
Page 2 - History Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from History Study. Real-time updates on events, politics, business and more.
July 31, 2023
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with...
July 19, 2023
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva Decision follows negative opinion by the Committee for Medicinal...
July 19, 2023
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva (FOP)Decision...
June 29, 2023
An FDA committee voted favorably on whether the available evidence supports the effectiveness of palovarotene for fibrodysplasia ossificans progressiva.
May 26, 2023
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million... | May 26, 2023
May 26, 2023
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals
April 23, 2023
Kean University is beginning a new research study into two key battles of the Revolutionary War that took place in New Jersey.
April 17, 2023
Kean University is beginning a new research study into two key battles of the Revolutionary War that took place in New Jersey.
March 16, 2023
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP PDUFA date has been set for 16 August 2023 following the New Drug Application
March 16, 2023
Investegate announcements from Ipsen Pharma, Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP